INTRODUCTION
STUDY GOALS AND OBJECTIVES
BCC’s goal in conducting this study is to determine the current status of the DNA diagnostics industry and to assess its growth potential over a 5-year period from 2008 to 2013. We are particularly interested in the markets for DNA microarrays, PCR-based assays, fluorescent in situ hybridization, and biochips.
In addition, we are interested in the market for DNA assays for specific clinical applications. For each, we examine the technology, development process, market penetration and the projected market for each diagnostic assay through 2013.
Our key objective is to present a comprehensive analysis of the current market and its future direction.
REASONS FOR DOING THE STUDY
DNA-based assays continue to move from research settings into the clinic and as such they represent one of the fastest growing segments of diagnostics. We are interested in the innovations in microarrays, PCR assays, biochips and other common technologies for DNA detection as they are modified for routine clinical use.
As nucleic acid testing becomes routine, a number of related issues have come to the fore including government regulation, reimbursement through insurance, patient confidentiality and other legal ramifications. These developments and their impact on the DNA diagnostics business are also covered in this report.
SCOPE OF REPORT
This study examines the global market for assays used to detect specific nucleic acid sequences in medical and life sciences applications. While the goal of all DNA-based diagnostic assays is similar, several different technologies can be employed. BCC analyzes each technology in detail and determines major players, current market status and presents forecasts of growth over the next 5 years. Scientific challenges and advances, including the latest trends, are emphasized.
We examine government regulations, major collaborations, recent patents and factors affecting the industry worldwide. In addition, we examine new directions for DNA diagnostic technologies and emerging applications in clinical diagnostics.
INTENDED AUDIENCE
This study will be of interest to technology and business professionals in the pharmaceutical, health care, genomics and biotechnology industries. Business development professionals, market analysts, consultants, and investors working in medical biotechnology will also find this report valuable.
METHODOLOGY AND INFORMATION SOURCES
The market assessments provided have been assembled based on publicly available information up to and including April, 2008. The base year for this report is 2008 and forecast data are provided through 2013. In cases where data for 2008 were not available, figures were extrapolated from 2007 statistics, half-year figures for 2007 and historical trends between 2003 and 2007. Market figures are based on current dollars, and inflation is not computed into the projection figures.
The information contained in this report has been assembled from both primary and secondary data sources. Primary research was conducted via telephone interviews with industry professionals, research scientists, physician-researchers and laboratory heads to discover the most recent developments in their fields of interest. Secondary data was collected via a comprehensive search of the scientific, peer-reviewed literature, clinical trial reports and databases, industry trade media, company websites, annual reports and industry press releases.
ANALYST CREDENTIALS
Amy Brock, Ph.D. has over 12 years of research experience working at the interface of the biological sciences, bioengineering and biophysics. Trained at the Massachusetts Institute of Technology and Harvard University, she holds a B.S. and Ph.D. in biomedical science. She is the author of several BCC reports including Medical Imaging: Equipment and Reagents (HLC020E), Biocompatible Materials for the Human Body (HLC010D), Kinase Inhibitors (BIO053A) and Diagnostics and Therapeutics for Genetic Disease (BIO056A)
Report Code: BIO063A, Published: June 2008, Analyst: Amy Brock
